With U.S. fatalities from COVID-19 now past 115,000, British scientists delivered some welcome news on Tuesday: A drug that appears to cut the odds of death in ventilated patients by one-third. The drug is a low-cost steroid called dexamethasone, which has been in use for decades, noted a team at the University of Oxford. In a trial of more than 6,000 patients, use of dexamethasone was also found to lower the death rate for slightly less-sick patients — those receiving oxygen but not on a ventilator — by about one-fifth. Dexamethasone was of no benefit to patients with milder cases of COVID-19. However, it “is the first drug to be shown to improve survival in COVID-19,” study co-lead investigator Peter Horby, professor of emerging infectious diseases at the University of Oxford, said in a statement, The New York Times reported. “The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment,” he added. According to Horby, given its cheap price tag and wide availability, there’s no reason why dexamethasone shouldn’t become the standard of care for severe cases of COVID-19. “Bottom line is, good news,” Dr. Anthony Fauci, who directs the U.S. National Institute of Allergy and Infectious Diseases, told the Associated Press. “This is a significant improvement in the available therapeutic options that we have.” One doctor’s… read on >







